Medtide (SEHK:3880) Net Margin Surge In 1H FY 2025 Tests Earnings Quality Concerns

Simply Wall St.03-31

Medtide (SEHK:3880) has just posted its FY 2025 first half numbers, with revenue of ¥253.8 million and basic EPS of ¥0.82, set against trailing twelve month revenue of ¥570.1 million and EPS of ¥1.63 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624080539?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-03-31 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624080539","market":"us","top_or_hot":-1,"title":"Medtide (SEHK:3880) Net Margin Surge In 1H FY 2025 Tests Earnings Quality Concerns","media":"Simply Wall St.","content":"<div>\n<p>Medtide (SEHK:3880) has just posted its FY 2025 first half numbers, with revenue of ¥253.8 million and basic EPS of ¥0.82, set against trailing twelve month revenue of ¥570.1 million and EPS of ¥1.63 ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3880/medtide-shares/news/medtide-sehk3880-net-margin-surge-in-1h-fy-2025-tests-earnin\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medtide (SEHK:3880) Net Margin Surge In 1H FY 2025 Tests Earnings Quality Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedtide (SEHK:3880) Net Margin Surge In 1H FY 2025 Tests Earnings Quality Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-31 21:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3880/medtide-shares/news/medtide-sehk3880-net-margin-surge-in-1h-fy-2025-tests-earnin><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Medtide (SEHK:3880) has just posted its FY 2025 first half numbers, with revenue of ¥253.8 million and basic EPS of ¥0.82, set against trailing twelve month revenue of ¥570.1 million and EPS of ¥1.63 ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3880/medtide-shares/news/medtide-sehk3880-net-margin-surge-in-1h-fy-2025-tests-earnin\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03880","symbol_name":"泰德医药","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3880/medtide-shares/news/medtide-sehk3880-net-margin-surge-in-1h-fy-2025-tests-earnin","article_id":"2624080539","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3880/medtide-shares/news/medtide-sehk3880-net-margin-surge-in-1h-fy-2025-tests-earnin","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2624080539","pubTimestamp":1774963251,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Medtide (SEHK:3880) has just posted its FY 2025 first half numbers, with revenue of ¥253.8 million and basic EPS of ¥0.82, set against trailing twelve month revenue of ¥570.1 million and EPS of ¥1.63 that sit alongside a reported year over year earnings growth figure of 267.3%. Over recent periods the company has seen revenue move from ¥197.5 million and EPS of ¥0.40 in the first half of FY 2024 to ¥244.8 million and EPS of ¥0.07 in the second half of FY 2024 and then to the latest ¥253.8...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"03880":"泰德医药","BK1141":"生命科学工具和服务"},"translate_title":"Medtide(SEHK：3880)2025财年上半年净利润飙升考验盈利质量担忧","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03880":0.9},"content_text":"Medtide (SEHK:3880) has just posted its FY 2025 first half numbers, with revenue of ¥253.8 million and basic EPS of ¥0.82, set against trailing twelve month revenue of ¥570.1 million and EPS of ¥1.63 that sit alongside a reported year over year earnings growth figure of 267.3%. Over recent periods the company has seen revenue move from ¥197.5 million and EPS of ¥0.40 in the first half of FY 2024 to ¥244.8 million and EPS of ¥0.07 in the second half of FY 2024 and then to the latest ¥253.8 million and ¥0.82 in FY 2025, while trailing twelve month net margin is presented at 38.1% compared with 13.4% a year earlier. This frames a narrative focused on stronger margin conversion and profit quality. See our full analysis for Medtide. With the headline numbers on the table, the next step is to see how this shift in revenue, EPS, and margins lines up with the widely followed narratives around Medtide’s growth potential and risk profile. Curious how numbers become stories that shape markets? Explore Community Narratives SEHK:3880 Earnings & Revenue History as at Mar 2026 AdvertisementMargins Backed By 38.1% TTM Net Income  Over the last 12 months Medtide recorded net income of ¥217.4 million on revenue of ¥570.1 million, which lines up with the reported 38.1% net margin compared with 13.4% a year earlier. Bullish investors point to this margin step up as a core part of the thesis, and the recent halves give them support:\n     Net income for 1H FY 2025 was ¥102.0 million on revenue of ¥253.8 million, whereas 2H FY 2024 showed ¥8.6 million on ¥244.8 million of revenue, so profitability in the latest half sits far above the recent low point. On a trailing basis, net income of ¥217.4 million compares with ¥59.2 million at the prior 12 month reference, which heavily supports the bullish angle that recent performance is anchored in stronger profit conversion rather than only top line movement.    Strong margin support like this is exactly what bullish investors look for when they argue that a business has turned a corner on profitability, which is why many dig deeper into the detailed narrative before taking a view on durability. 📊 Read the what the Community is saying about Medtide. Earnings Growth Story Behind 267.3%  The trailing 12 month earnings growth figure is reported at 267.3%, and across the past five years earnings are described as compounding at 28.5% per year, while within that period semi annual EPS moved from ¥0.40 in 1H FY 2024 to ¥0.07 in 2H FY 2024 and then to ¥0.82 in 1H FY 2025. Bulls argue that these earnings patterns show a business scaling up, and the recent data gives them several talking points as well as some questions:\n     The latest 1H FY 2025 net income of ¥102.0 million versus ¥50.6 million in 1H FY 2024 fits with the 5 year 28.5% earnings CAGR reference, which supports the bullish claim that profitability has not only appeared recently but has been building across multiple years. At the same time, the sharp drop to ¥8.6 million in 2H FY 2024 inside that overall trend means the bullish view needs to explain a swing between halves even though the full trailing 12 month line still lands on a very strong earnings improvement headline.    23% Revenue Forecast Meets 12.5x P/E  Revenue is described as being forecast to grow about 23% per year and the shares trade on a P/E of 12.5x, which sits below peer and Asian Life Sciences industry averages of 29.1x and 35.2x respectively, while the current share price of HK$21.70 is also below the stated DCF fair value of HK$49.44. Supporters of the bullish view often link these valuation references to the recent operating performance, and the numbers here provide concrete inputs for that comparison:\n     The trailing 12 month revenue line of ¥570.1 million matches the growth narrative, so fans of the story see a combination of this scale with the 38.1% net margin as a reason why a 12.5x P/E might be seen as low next to peers at 29.1x and an industry marker at 35.2x. For investors who focus on modeled values, the gap between the DCF fair value of HK$49.44 and the HK$21.70 share price is large, which reinforces the bullish view that current pricing does not fully reflect the reported earnings trajectory and margin profile.    Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Medtide's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. The earnings story here is clearly optimistic, so this is a good time to review the numbers yourself and test how they stack up. To see exactly what others view as the key positives, review the 3 key rewards See What Else Is Out There The earnings path between halves, including the ¥8.6 million result in 2H FY 2024, raises questions about how consistent Medtide’s profitability and earnings quality really are. If that kind of earnings swing makes you cautious, compare it with companies screened for more resilient profiles using the 262 resilient stocks with low risk scores  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624080539","isCrawlerRequest":true}